← Product Code [FMI](/submissions/HO/subpart-f%E2%80%94general-hospital-and-personal-use-therapeutic-devices/FMI) · K132583 # EZ-IO INTRAOSSEOUS INFUSION SYSTEM (K132583) _Vidacare Corporation · FMI · Feb 11, 2014 · General Hospital · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/HO/subpart-f%E2%80%94general-hospital-and-personal-use-therapeutic-devices/FMI/K132583 ## Device Facts - **Applicant:** Vidacare Corporation - **Product Code:** [FMI](/submissions/HO/subpart-f%E2%80%94general-hospital-and-personal-use-therapeutic-devices/FMI.md) - **Decision Date:** Feb 11, 2014 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 880.5570 - **Device Class:** Class 2 - **Review Panel:** General Hospital - **Attributes:** Therapeutic, Real-World Evidence, Pediatric ## Real-World Evidence | Submission | Device | Sponsor | RWD Sources | RWE Use Summary | Key Tags | | --- | --- | --- | --- | --- | --- | | K132583 · Feb 11, 2014 | EZ-IO INTRAOSSEOUS INFUSION SYSTEM | Vidacare Corporation | Published clinical literature (Frascone et al., 2009) reporting on routine clinical use by EMS providers | The sponsor utilized findings from a published clinical study of routine EMS practice to justify expanding the weight range indication for the 25 mm needle set, citing observations regarding soft tissue depth as the limiting factor for successful insertion. | EMS clinical practice; Pediatric intraosseous access; Label expansion; Clinical literature | ### Clinical Evidence | Study Design | Population | Comparator | Key Endpoints | | --- | --- | --- | --- | | Use of the pediatric EZ-IO needle by emergency medical services providers (Frascone et al., 2009); Clinical study of routine clinical practice | Pediatric patients requiring intraosseous access | Not applicable for this study | Successful insertion and limiting factors (soft tissue depth) | ## Indications for Use The EZ-IO Intraosseous Infusion System provides intraosseous access in the proximal tibia, distal tibia and humeral head (proximal humerus) of adult and pediatric patients when intravenous access is difficult or impossible to obtain in emergent, urgent, or medically necessary cases for up to 24 hours. ## Device Story The EZ-IO Intraosseous Infusion System facilitates vascular access via the bone marrow. The system consists of a needle set (stylet and catheter) and a reusable cordless driver or manual handle. Clinicians identify anatomical landmarks, clean the site, and use the driver or handle to advance the needle through the bone cortex into the medullary space. A tactile 'pop' or 'give' indicates successful entry. The driver is detached, the stylet is removed, and the remaining Luer-lock catheter allows for the administration of fluids and medications. The device is used in clinical settings by healthcare providers. This submission expands the weight range for the 25 mm needle set from 40 kg or over to 3 kg or over to accommodate anatomical variability in soft tissue depth, allowing clinicians to select the appropriate needle length based on patient anatomy rather than weight alone. ## Clinical Evidence No new clinical trials were conducted. Evidence supporting the label change includes cadaveric pediatric studies and previously published clinical literature (Frascone et al., 2009) evaluating the use of pediatric EZ-IO needles by EMS providers. These studies demonstrate that the 25 mm needle length is safe and often necessary for patients under 40 kg due to variations in soft tissue depth over the insertion site. ## Technological Characteristics Needle sets are single-use, composed of 304 stainless steel with polycarbonate hubs. Available in 15 mm, 25 mm, and 45 mm lengths. Features depth markers on the catheter. Connects to a reusable cordless driver or manual handle via a magnetic disc. Driver is battery-powered. No changes to materials, design, or sterilization compared to predicates. ## Regulatory Identification A hypodermic single lumen needle is a device intended to inject fluids into, or withdraw fluids from, parts of the body below the surface of the skin. The device consists of a metal tube that is sharpened at one end and at the other end joined to a female connector (hub) designed to mate with a male connector (nozzle) of a piston syringe or an intravascular administration set. ## Predicate Devices - EZ-MIO Distal Tibia, EZ-IO Distal Tibia; EZ-IO (formerly Vidaport) Intraosseous Infusion System; EZ-IO Humeral Head ([K091140](/device/K091140.md)) - Powered PD IO Infusion System; EZ-IO Humeral Head; Powered PD-IO ([K101026](/device/K101026.md)) ## Reference Devices - Bone Injection Gun Adult Proximal Tibia Humeral Head ([K981853](/device/K981853.md), [K062940](/device/K062940.md)) - Cook Intraosseous Infusion Needles ([K915409](/device/K915409.md), [K913258](/device/K913258.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ K132583- [Traditional 510(k)] EZ-IO Intraosseous Infusion System by Vidacare Corporation October 30, 2013 # 005_510(k) Summary (Revised) [807.92(c)] vidacare 4350 Lockhill Selma Road Shavano Park, TX 78249+2095 210-375-8500 www.vidacare.com #### SUMMARY (Revised) Submitter's name [807.92(a)(1)]: Vidacare Corporation Address: 4350 Lockhill Selma Road 210-375-8500 Shavano Park, TX 78249-2095 Phone: 210-375-8537 Fax number: Name of contact person: Larry Miller, MD, CMO/ Diana Montez, BSN, RN Date Summary was prepared: October 30, 2013 [807.92(a)(2)]: EZ-IO Intraosseous Infusion System Trade Name of the devices: Intraosseous Infusion System Common or usual name: Hypodermic single lumen needle Classification name: The legally marketed devices to which we are claiming equivalence [807.92(a)(3)]: | 510(k) number | Trade or Proprietary or
Model Name | Manufacturer | |---------------|---------------------------------------------------------------------------------------------------------------------------------|----------------------| | K091140 | EZ-MIO Distal Tibia,
EZ-IO Distal Tibia; EZ-IO
(formerly Vidaport)
Intraosseous Infusion System;
EZ-IO Humeral Head | Vidacare Corporation | | K101026 | Powered PD IO Infusion
System; EZ-IO Humeral
Head; Powered PD-IO | Vidacare Corporation | {1}------------------------------------------------ | 510(k) number | Trade or Proprietary or
Model Name | Manufacturer | |--------------------|-------------------------------------------------------------|------------------| | K981853
K062940 | Bone Injection Gun™ Adult
Proximal Tibia
Humeral Head | Waismed | | K915409
K913258 | Cook Intraosseous Infusion
Needles | Cook Medical Inc | ## Device Description [807.92(a)(4)]: The EZ-IO Intraosseous Infusion System including previously cleared K091140 EZ-MIO Distal Tibia, EZ-10 Distal Tibia; EZ-10 (formerly Vidaport) Intraosseous Infusion System ; EZ-IO Humeral Head and K101026 Powered PD IO Infusion System; EZ-IO Humeral Head; Powered PD-IO is designed to allow the user to insert a needle set consisting of a stylet and catheter through the cortex of the bone to a desired depth within the bone marrow to facilitate intraosseous infusion of desired fluids for vascular access. All system materials are medical grade. Needle sets are single-use and composed of 304 stainless steel with polycarbonate hubs and available in 15 mm (3-39 kg); 25 mm (40 kg or over) and 45 mm (40 kg or over). Black lines on the needle set catheter serve as depth markers. The needle sets connect to the driver/drill/ manual handle shaft with a magnetic disc. The reusable cordless driver/drill is powered by lithium batteries with a battery-power indicator light. The EZ-MIO consists of a manual handle device which is primarily used by the armed forces. Clinicians locate anatomical landmarks and clean the insertion site. Using the cordless driver or manual handle with needle set attached the needle set is pressed through the soft tissue to the outer cortex of the bone. Depth markers on the catheter must be visible prior to powering driver or manually inserting the needle set to ensure placement within the medullary space. If using the powered driver clinicians then squeeze the driver trigger and apply moderate, steady pressure. Trigger is released when a sudden "give" or "pop" is felt, which indicates entry into medullary space; the catheter will not always be inserted to the hub. If using the manual handle, clinicians apply downward pressure and rotation through the bone until a change in pressure is felt as a "give" or "pop" or desired depth is reached. For both methods after insertion of the needle set, the driver unit is detached from the needle set, leaving the stylet and cannula firmly seated in the bone. The stylet is then separated and removed from the catheter by turning the stylet hub counter clockwise leaving a standard Luer lock catheter securely seated in the bone. The catheter Luer lock permits attachment of standard syringes and IV tubing for administration of medications and fluids. {2}------------------------------------------------ This submission requests a label change only to the 25 mm needle set from "40 kg or over" to" 3 kg or over" utilizing the same technique and devices previously cleared via 510(k)s K091140 and K101026. ### Proposed Expanded Weight Range for the 25 mm needle set: Vidacare is requesting a label change only to the 25 mm needle set from "40 kg or over" to "3 kg or over" to provide clinicians with an option to choose the correct needle length not only based on weight but also variability in each patient's anatomy. Due to differences in the amount of soft tissue overlying the target anatomical area, many patients less than 40 kg require additional needle length the 25 mm offers over the 15 mm needle length. This has been noted by authors in a clinical study which stated the limiting factor for successful insertions is the amount of tissue covering the approved insertion site.1 Cadaveric pediatric studies with representative photographs demonstrate the 25 mm length to be safe and often necessary in patients less than 40 kg (see RTA response section J number 36 Performance Data included with this response package). There would be no change in the Directions for Use as insertion technique is the same. In consideration of our cited predicate similarities, performance data, observations noted in the cited clinical studies and Vidacare's experience with the EZ-IO Intraosseous Infusion System we conclude that expanding the weight range for the 25 mm needle set is a safe and correct modification. This modification will allow clinicians to choose the correct needle length based on the best anatomical site option, soft tissue depth over the insertion site with a wider weight range that more accurately suits patients' anatomy and needs, with a weight range of 3 kg or over . 1. Frascone RJ, Jensen J, Wewerka SS, Salzman JG. Use of the pediatric EZ-IO needle by emergency medical services providers. Pediatric Emergency Care 2009;25(5):329-32. ## [807.92(a)(5)]: ## (Proposed)Indications for Use: The EZ-10 Intraosseous Infusion System provides intraosseous access in the proximal tibia, distal tibia and humeral head (proximal humerus) of adult and pediatric patients when intravenous access is difficult or impossible to obtain in emergent, urgent, or medically necessary cases for up to 24 hours. The above proposed Indications For Use provide the same indication as the predicate devices but is presented in a condensed version. {3}------------------------------------------------ # [807.92(a)(6)]: # Summary of the technological characteristics of our device compared to the predicate devices: The labeling change requires no new technology to facilitate the safe application of the product. There have been no changes to the design or components of the Vidacare devices cleared under K091140 and K101026 and therefore, the comparison of technological characteristics listed below are identical: - Target Population . - Driver Design Features . - . Needle Design - Technique . - Anatomical Sites . - Sterility . - Biocompatibility . - Where Device is Used (types of facilities/environments) . - Types of Clinicians (that would use device) . For predicates K981853, K062940 The Bone Injection Gun and K915409, K913258 Cook Intraosseous Infusion Needles the following characteristics are similar or identical: - . Target Population - Needle Design . - Technique: . - . For insertion -Cook and EZ-MIO devices - For locating correct sites; validating insertion; indications and . contraindications - Anatomical sites . - . Sterility - Biocompatibility . - Where Device is Used (Types of facilities/environments) . - Types of Clinicians (that would use device) . {4}------------------------------------------------ Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a stylized depiction of an eagle or bird-like figure with three curved lines representing its wings or body. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the bird-like figure. Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 February 11, 2014 Vidacare Corporation Dr. Larry Miller CMO 4350 Lockhill Selma Road Shavano Park, TX 78249 Re: K132583 Trade/Device Name: EZ-IO Intraosseous Infusion System Regulation Number: 21 CFR 880.5570 Regulation Name: Hypodermic Single Lumen Needle Regulatory Class: II Product Code: FMI Dated: August 19, 2013 Received: August 21, 2013 Dear Dr. Miller: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. {5}------------------------------------------------ Page 2 - Dr. Miller Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its tollfree number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Sincerely yours, Image /page/5/Picture/7 description: The image shows the text "Kwame Ulmer-s" in a stylized font. The text is arranged in two lines, with "Kwame" on the top line and "Ulmer-s" on the bottom line. There is a logo to the right of the text, which appears to be a circle with a design inside and a triangle with a design inside. for Erin I. Keith, M.S. Acting Director Division of Anesthesiology, General Hospital, Respiratory, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {6}------------------------------------------------ # Premarket Notification [Special 510(k)] Device Modification: Vidacare Corporation August 12, 2013 #### 6. Indications for Use Statement Indications for Use 510(k) Number (if known): _K132583 #### Device Name: The EZ-IO Intraosseous Infusion System provides intraosseous access in the proximal tibia, distal tibia and humeral head (proximal humerus) of adult and pediatric patients when intravenous access is difficult or impossible to obtain in emergent, urgent, or medically necessary cases for up to 24 hours. Prescription Use X ___________________________________________________________________________________________________________________________________________________________ Over-The-Counter Use ------- (Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED) ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ AND/OR Concurrence of CDRH, Office of Device Evaluation (ODE) FDA Digitally signed by Richard C. Chapman Date: 2014.02.10 16:20:00 -05'00' --- **Source:** [https://fda.innolitics.com/submissions/HO/subpart-f%E2%80%94general-hospital-and-personal-use-therapeutic-devices/FMI/K132583](https://fda.innolitics.com/submissions/HO/subpart-f%E2%80%94general-hospital-and-personal-use-therapeutic-devices/FMI/K132583) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com